CD274 and breast carcinoma: In a preclinical study evaluating PD-L1 as target for molecular imaging in an immunocompetent breast cancer model, Josefsson et al. provided biodistribution and dosimetry data supporting the feasibility of using a radiolabeled anti-PD-L1 mAb not only for molecular imaging but also for targeted radionuclide therapy (TRT) [31].